Prostate Cancer
CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer.
December 25, 2024
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.
December 25, 2024
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
December 25, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.
December 24, 2024
Partial or Focal Brachytherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
December 24, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
December 24, 2024
Surface-Based Ultrasound Scans for the Screening of Prostate Cancer.
December 24, 2024
Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
December 23, 2024
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.
December 23, 2024
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).
December 23, 2024
Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer.
December 23, 2024
Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.
December 23, 2024
Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.
December 20, 2024